

[Drug Databases \(https://www.fda.gov/Drugs/InformationOnDrugs/\)](https://www.fda.gov/Drugs/InformationOnDrugs/)

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

[Home \(index.cfm?resetfields=1\)](#) | [Back to Product Details](#)

Additional Information about Patents

- Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
- Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
- As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N022561

Product 001
CLADRIBINE (MAVENCLAD) TABLET 10MG

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
001	7713947	10/16/2026			<u>U-2520</u>		05/28/2019
001	7888328	04/11/2024		DP	<u>U-2521</u>		05/28/2019
001	8377903	05/31/2026			<u>U-2522</u>		05/28/2019
001	8785415	04/11/2024		DP	<u>U-2523</u>		05/28/2019
001	10849919	11/23/2038			<u>U-3411</u>		09/09/2022

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration

Product No	Exclusivity Code	Exclusivity Expiration
001	<u>NP</u>	03/29/2022

[View a list of all patent use codes \(results_patent.cfm\)](#)

[View a list of all exclusivity codes \(results_exclusivity.cfm\)](#)